Astellas and Teva Reached a Settlement Agreement on VESIcare® Patent Case

Astellas Pharma Inc. and its US subsidiary, Astellas Pharma US, Inc. ("Astellas") and Teva Pharmaceutical USA, Inc. ("Teva") announced today that the three companies have reached an agreement to settle the pending U.S. litigation with regard to US Patent No. 6,017,927 for VESIcare® (solifenacin succinate) tablet through the entry of a consent judgment. VESIcare is a treatment for the overactive bladder. As a result of this settlement, the case will be terminated by the consent judgment. The settlement of the litigation provides Teva with the opportunity to launch a generic solifenacin succinate product in October, 2018 if Astellas does not obtain pediatric exclusivity. Further terms of the settlement will not be disclosed. Astellas and Teva Reached a Settlement Agreement on VESIcare® Patent Case (pdf27 KB) Contact the Media Relations team Communications & Investor Relations Main phone line for Media: ＋81-3244-3201 Business hours (JST) From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm (closed on Saturdays, Sundays, national holidays and company holidays)

The release as fetched from its publisher. astellas.com ↗